Angiotensin II Receptor Antagonists Supplementation is Associated with Arterial Stiffness: Insight from a Retrospective Study in 116 Peritoneal Dialysis Patients

Figures & data

Table 1 Characteristics of the peritoneal dialysis patients

n = 116	Mean	±SD
Gender (M/F)	35/81
Age	48	±10
BMI (kg/m²)	22.3	±3.0
SBP (mmHg)	141	±27
DBP (mmHg)	86	±17
PP (mmHg)	56	±14
baPWV (cm/s)	1751	±458
Alb (g/dL)	3.9	±0.4
TC (mg/dL)	204	±48
Duration (month)	52	±3
Smoking	9/116
Alcohol	6/116
Calcium containers (mg/day)	2195	±1358
Vitamin B (tablets/day)	1.3	±0.9
Folic acid (mg/day)	3.7	±1.9
ACEI	5/116
ARB	31/116
β-blockers	41/116
Calcium-channel blockers	56/116

Abbreviations: BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, PP = pulse pressure, baPWV = brachial-ankle pulse wave velocity, Alb = serum albumin, TC = total cholesterol, ACEI = angiotensin-converting enzyme inhibitors, ARBs = angiotensin II receptor antagonists, smoke and alcohol = number of subjects having history of smoking and alcohol drinking.

Table 2 Results of step-wise multiple regression analysis to assess the correlation of baPWV with other variables

Covariate	Standard β	t value	p
SBP (mmHg)	0.61	8.40	<0.001
Age	0.39	5.56	<0.001
BMI (kg/m²)	−0.23	−3.19	0.002
ARBs	−0.17	−2.35	0.021

Abbreviations: baPWV = brachial-ankle pulse wave velocity, SBP = systolic blood pressure, BMI = body mass index, ARBs = angiotensin II receptor antagonists.

Figure 1. No significant difference of blood pressures (systolic, diastolic, pulse pressure) in patients with different kinds of antihypertensive medications (i.e., group A, without hypertension and no antihypertensive medications; group B, using ARBs; group C, using β-blockers; group D, using calcium-channel blockers. group E, using ARBs combing calcium-channel blockers or β-blockers or both; group F, using Ca-blockers and β-blockers). *p < 0.05 vs. group A; ψ: p > 0.05 vs. group B.